CFDE Data Portal | Search LINC02709

	Label	Description
	LINC02709 Gene (Entity type)	ENSG00000245522 - long intergenic non-protein coding RNA 2709
	GSE233679 nicotinamide 14 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE161897 MBNL knockout 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE224105 GSE224108 zearalenone 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE143782 calcitriol 3 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE101754 FXR1 knockdown NCI-H358 5 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE161800 cisplatin A-549 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 5 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE142975 G9a knockdown RD 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS

LINC02709

ENSG00000245522 - long intergenic non-protein coding RNA 2709

GSE233679 nicotinamide 14 v 15 human up

A Gene Set from LINCS

GSE161897 MBNL knockout 2 v 1 human dn

A Gene Set from LINCS

GSE224105 GSE224108 zearalenone 3 v 2 human up

A Gene Set from LINCS

GSE143782 calcitriol 3 v 4 human up

A Gene Set from LINCS

GSE101754 FXR1 knockdown NCI-H358 5 v 2 human dn

A Gene Set from LINCS

GSE161800 cisplatin A-549 0 v 2 human up

A Gene Set from LINCS

GSE226249 pirfenidone HL 5 v 6 human up

A Gene Set from LINCS

GSE142975 G9a knockdown RD 1 v 0 human up

A Gene Set from LINCS

GSE195663 cisplatin 0 v 3 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.